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The need for digestibility in the pharmaceutical
field
Hannes Wahlroos
Professor,  Director General
National Agency for Medicines (NAM)
Editorial
Everyone knows how important moderation is in
eating and drinking at Christmas time. Enjoying fes-
tive delicacies can otherwise lead to bloating and in-
digestion. Restraint must similarly be observed in
implementing pharmaceutical reforms, otherwise the
pharmaceutical field will not be able to swallow
them. 
Many significant pharmaceutical reform projects
have been overshadowed by discussions relating to
organisational matters. Projects need to be imple-
mented purposefully, but presence of mind and fore-
thought must not be neglected. Management and co-
ordination of the whole is essential. There are also
risks involved in trying to do everything at the same
time. 
The introduction of electronic prescriptions,
which has been postponed for many years, is now
imminent – it is set to take place in 2011. The rele-
vant authorities and players in this area are currently
making preparations. When patients and profession-
als are granted access to patients’ medical histories
and details of all prescriptions, this will present an
entirely new situation for patients, doctors and phar-
macies. The prescription system and the drug supply
chain will change, methods for preventing overlap-
ping medications and incompatibilities will improve,
the possibilities for carrying out research into drug
use will be developed, and counterfeit prescriptions
will be encountered less frequently. It must be en-
sured that final details do not prove a stumbling
block, and that the expected benefits of electronic
prescriptions are indeed achieved. This project
should signal the start of a new era.
The reference price reform was dominated by the
debate on pharmaceutical patents. There has been
little discussion about any of the other effects of the
reform, such as the increased need for patients to re-
ceive information at the doctor’s surgery or in the
pharmacy. Even at this stage of the prescription
process, the patient should be made aware of the ba-
sis on which the reimbursement will be calculated in
the pharmacy. This will pose a challenge both for
doctors and for pharmaceutical staff in the pharma-
cies. The reform also poses financial challenges, es-
pecially for pharmaceutical companies, pharmaceuti-
cal wholesalers and pharmacies. Competition in the
pharmaceutical industry is becoming ever tougher.
All activities need to be economically efficient, but
players in this sector are also expected to display a
high level of professionalism and skill in managing
their responsibilities. Is this yet another Christmas
nut that needs to be cracked?
In the autumn, two significant draft laws pre-
pared by NAM were sent out by the Ministry of So-
cial Affairs and Health to players in the fields of
pharmaceuticals and medical devices, to allow them
to submit a statement. In addition to safeguarding
pharmaceutical services in the outlying districts,
amendments to the Medical Act should also ensure
the introduction of online pharmacy services, im-
proved mechanical dosage distribution, more restric-
tive measures for advertising of medicines, and in-
creased transparency. The pace of progress of the
proposals will become clear in the spring, but in any
case the proposals must be faced. Any delay in the
reforms will lead to an accumulation of problems in
the pharmaceutical sector.
As regards medical devices, NAM’s proposal in-
volves not only improving patient safety, but also a
reform of all present legislation. Enterprises operat-
ing in the field, professional users, health care provi-
sion units and the regulatory authorities must each
accept their obligations and responsibilities. Collabo-
ration within the EU on the regulation of medical
devices further increases the interface synergy with
pharmaceutical regulation.
And the EU has some goodies of its own up its
sleeve. The expected proposals for directives on
pharmacovigilance, drug information and the pre-
vention of drug counterfeits will provide plenty of is-
sues for us to digest next Christmas, too.
Despite the pace of the reforms, on behalf of
NAM I have the pleasure of wishing all readers a
peaceful Christmas time.
Inadequate discussion of adverse events in drug
presentations in Finland
In 2007 the National Agency for Med-
icines drew up a recommendation for
quality criteria to be applied to drug
presentations to assess the factual con-
tent of pharmaceutical marketing (1).
The question of whether these recom-
mendations were successfully intro-
duced into practice was discussed in
collaboration with the Centre for
Pharmacotherapy Development ROH-
TO in the spring of 2008. The results
of the survey are based on assessments
made by 17 general practitioners
which were focussed on the factual
content and quality of the drug presen-
tations arranged at their surgeries. The
survey covered 83 drug presentations
and revealed the details of the extent
to which the data made available at
these presentations corresponded with
the information contained in the sum-
maries of product characteristics and
with the need that doctors have for in-
formation.
For pharmaceutical companies,
drug presentations constitute a signifi-
cant part of the company’s marketing
of prescription drugs to the medical
professionals who are entrusted with
prescribing and delivering drugs to the
public. A pharmaceutical representa-
tive gives an average of 3 to 5 presen-
tations a day. Doctors participate in 2
to 3 one-to-one drug presentations on
average per month and in 4 to 5 group
presentations per month (3). For doc-
tors, drug presentations at their best
provide quality and up-to-date infor-
mation about drugs and drug treat-
ments as a whole (1, 2). Drug presen-
tations will decrease in numbers in the
future (4). The number of product spe-
cialists and drug firm representatives
has decreased by 17% in the last three
years (3).
Background
We set out by establishing whether the
information given orally at drug pre-
sentations has been appropriate as re-
gards the quality requirements stipulat-
ed for these presentations. 
Conclusions
The results of the survey show that
slightly more than half (60%) of the
drug presentations held at health care
centres comply well with the recom-
mendations for quality criteria relating
to SPCs, price information and other
written material. The results support
the impression that drug presentations
held during working hours are appro-
priate in the main, but in presentations
of a short duration (40% of the pre-
sentations last less than 10 minutes) it
appears that the products are not cov-
ered as fully as possible, but instead,
the drug firm representative leaves
background material for the doctor to
browse through, making a mention of
clinical trials, and instead of a long
presentation the representative also
mentions the price but makes no price
comparisons.
Clinical drug trials are very often re-
ferred to, in as many as 94% of the
presentations. Therapeutic indications
for the products discussed at the presen-
tations almost always corresponded to
the information contained in the SPCs.
According to experts at ROHTO, the
therapeutic indications for products had
clearly been expanded in four, and pos-
sibly in twelve of the presentations, out
of the total of 83 assessed. 
Details of the safe use of drugs
should be focussed on more during
drug presentations. Adverse reactions
were only described on 19 occasions in
the presentations assessed. Drug inter-
actions or contraindications were dis-
cussed only in 10 presentations, and
other issues pertaining to safe use of
the drug were mentioned in only 32 of
the presentations. 
The results of this survey are simi-
lar to those disclosed by other surveys
of factual content in drug presenta-
tions in Finland and other countries
(6–14). Several surveys have main-
tained that drug presentations focus
mainly on the positive issues and ad-
vantages in comparison with other
drugs and alternative therapies. Drug
safety issues, adverse reactions and/or
interactions are too infrequently dis-
cussed at the presentations (6–10, 13).  
The survey material is considered a
reliable assessment of the quality of
drug presentations held in the spring
of 2008. According to this survey, the
quality and informational content of
drug presentations can be improved by
providing more details about the sig-
nificance of the drug as a whole in
comparison with other forms of thera-
py, and by adding further details about
the product’s adverse effects and its in-
teractions and other issues associated
with safe use. Presentations should ful-
fil the doctors’ need for information,
for example by providing more infor-
mation about the epidemiological rele-
vance of the product, current treat-
ment recommendations, and the cost-
effectiveness of medicinal products. Of
the information provided at drug pre-
sentations in Finland in general, 94%
corresponded to the content of the
SPC of the particular drug, omitting
nevertheless a significant amount of in-
formation. In 42 of the presentations
in the survey no adequate details of the
drug safety issues were given.
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One of the most remarkable advances
of medical sciences in the early 20th
century was the cure of rickets and os-
teomalacia by vitamine D. About half
a century later it was evident that vita-
mine D actually was an endogenous
hormone that in the North was needed
as a food supplement during the win-
ter months. The active vitamin D, cal-
citriol is a hormone produced by the
kidney. Its previtamin, cholecalciferol
(D3), is synthetized in the skin via the
photolytic activity of UVB-radiation.
D3 is then transported protein bound
into liver to be hydroxylated to calcidi-
ol (25(OH)-D), which is the substrate
for another hydroxylation in the kid-
ney to produce the final product cal-
citriol (1,25(OH)2-D). 
Now, 200 years after the first docu-
mented use of cod liver oil to cure rick-
ets and 100 years after discovery of its
active ingredient, the effects of vitamin
D have proved to be much more di-
verse than just supporting homeostasis
of the bone. Calcitriol modulates via its
nuclear receptor the expression of hun-
dreds of genes related to its own me-
tabolism, immune response and cell
growth. Furthermore, acute effects
such as stimulation of calcium trans-
port appear to be mediated via a cell
membrane receptor of vitamin D. 
The non-skeletal health benefits of
vitamin D are related to prevention of
hypertension, cancer and autoimmune
diseases. Since the present evidence is
mainly epidemiological, more long
lasting randomized studies are needed
to substantiate the initial findings and
to define optimal plasma concentra-
tion of calcidiol 25(OH)-D, which is
used to measure the vitamin D bal-
ance. Gaining of the health effects of
vitamin D probably requires higher
plasma levels than needed to prevent
bone disease. Today we know that at a
concentration of less than 10 mmol/l
of calcidiol the production of the ac-
tive vitamin calcitriol decreases. To
prevent rickets a level of about 20
nmol/l is needed. Plasma concentra-
tions of more than 40 mmol/l are con-
sidered “normal” although the people
of southern countries appear to have
concentrations between 100–200
nmol/l. According to animal experi-
ments and human cases D-vitamin
Vitamin D – Southern hormon and Northern vitamin
Crushing of depot tablets may cause overdoses
marketed in Finland include the follow-
ing or similar warning: Depot tablets
must be swallowed as a whole. They
may not be broken, chewed or crush-
ed. Breaking, chewing or crushing of
the tablet may lead to a rapid release
of oxycodon which may then be ab-
sorbed in the system in life-threatening
amounts. Phentanyl is also an opiod
analgesic, and respiratory depression is
also a risk related to its use. In depot
tablet/capsule the effect of an individual
dose has been prolonged by regulating
the release of the medicinal substance
from the tablet/capsule. This release can
be regulated by several mechanisms,
but mainly the tablet/ capsule should
remain as a whole in order to this regu-
lating system to function.
Swallowing difficulties due to vari-
ous reasons are prevalent among elder-
ly patients. Also crushing of tablets or
opening of capsules is common, and
During autumn 2008 the National
Agency for Medicines received an ad-
verse drug reaction report related to
oxycodon sustained release tablets: 
A female patient, around 60 years old,
suffered from metastasised lung cancer,
and was receiving oxycodon depot
tablets for the treatment of pain. One
morning she was having swallowing dif-
ficulties, and the oxycodon depot tablets
were given to her crushed. During the
same morning she developed shortness
of breath. She received oxycodon oral
solution as further pain medication, and
in the afternoon a phentanyl patch was
attached to her skin. She expired within
two hours from that.
Oxycdon is an opioid agonist, and the
most significant risk related to its use is
respiratory depression. Depot tablets re-
lease the active ingredience slower than
short-acting oxycodon preparations, and
the SPC for oxycodone depot tablets
toxicity (e.g., calcification of soft tis-
sues) is associated with constant plas-
ma levels of over 300–500 nmol/l. 
The optimum level of 25(OH)-D
of 80–100 nmol/l is suggested by the
following: a) the natural UVB-induced
concentration is not exceeded, 
b) the absorption of calcium is optimal
while no hypercalcemia is present,
c) the suppression of the parathyroid
hormone is maximal, d) the hydroxy-
lation of D3 by the liver is not saturat-
ed, i.e., no accumulation of the D3 in
the fat and muscular tissue occurs,
and, e) clinical evidence shows benefi-
cial effects on bone density and pre-
vention of fractures.
The experts in the US and Canada
have recently recommended a daily
supplementation of 1 000–2 000 IU of
vitamin D3 instead of the traditional
400 IU usually present in a spoonful
of cod liver oil. Due to confounding
factors (sun exposure, diet and age)
only time will show the impact of such
a recommendation on the average vit-
amin level in the population.
Ilari Paakkari, M.D., Ph.D., professor
Institute of Biomedicine, Pharmacology
University of Helsinki
according to one estimate it occurs at
least once a week in over 80% of nurs-
ing homes. Crushing of tablets is asso-
ciated with risks related to hygiene and
spillage, and even allergic reactions are
a risk through contamination of medi-
cines. Especially one must keep in
mind that crushing of depot tablets
and other modified release formula-
tions may cause rapid release of the
medicinal substance and adverse reac-
tions and overdose symptoms. 
If the patient has swallowing diffi-
culties, one should check from the SPCs
of his/her medications if a regular or a
depot tablet is in question. Primarily a
more suitable preparation should be
sought (e.g., liquid form) that may be
crushed), in collaboration with the pre-
scribing physician. Also the marketing
authorisation holder or pharmacy may
be contacted for further information.
Tiina Karonen, Senior Medical Officer
Recurrent anaphylaxis associated with respiratory
infection
Our patient
A 50-year-old healthy male patient
attended the dermatology outpa-
tient clinic at the University Hospi-
tal of Turku; he had been referred
by a health centre general practi-
tioner for a review due to an ana-
phylactic reaction which had re-
curred on two occasions. The pa-
tient was not receiving any regular
medication. He occasionally used
aspirin or ibuprofen for aches or
symptoms of influenza. He was
not aware of being allergic to any-
thing, but said that he suffered
large swellings from midge bites.
At school age he had suffered from
a rash over the carpometacarpal
joint which was thought to be
atopic. It was treated with corti-
costeroid ointments, and no fur-
ther rash occurred in adulthood.
Thyrotoxicosis, which he had de-
veloped in his twenties, had been
treated with surgery and a some-
what short course of medication
until he was symptom-free.
At Christmas 2000 the patient
had a respiratory infection which
was treated with cephalexin thera-
py prescribed by a doctor, in addi-
tion to which the patient also used
aspirin and throat lozenges bought
over-the-counter (OTC) from the
chemist’s. After a two-day course
of antibiotics the patient within
less than an hour of taking his
medicine developed severe dysp-
noea together with oedema of the
tongue, pharynx and face. He
managed to get to an emergency
treatment unit, and the condition
was relieved with adrenaline. After
this episode special restrictions of
medication were not considered
necessary, and cephalexin therapy
was later used without problems.
In spring 2007, in association
with respiratory infection, facial
and pharyngeal oedema recurred,
together with generalised urticaria.
Before the flare-up of this reaction
the patient had treated himself
symptomatically with ibuprofen
and throat lozenges. The doctor
who had given the emergency treat-
ment referred the patient for allergy
assessment later.
Skin prick tests were carried out
to reveal the ethiology of the ana-
phylactic reaction(confirm the diag-
nosis of anaphylaxis). On arrival
for the test the patient brought with
him an over-the-counter throat
lozenge, which was crushed, and a
prick test carried out using this re-
sulted in a reaction (8 mm) which
was greater than that caused by his-
tamine (5 mm), as also was that us-
ing chlorhexidine (0,5% in water)
(9 mm). The throat lozenge also
contained benzocaine, which did
not cause skin test reactions. The
patient had taken this particular
throat lozenge twice previously,
once in 2000 and on another occa-
sion in 2007. The medical oint-
ments used for hand rash in child-
hood, which probably contained
chlorhexidine, had not as far as the
patient could remember caused any
skin reaction. But some of the oint-
ments containing a corticosteroid
and chlorhexidine used for a leg
rash in recent years in fact caused
further reddening of the skin in-
stead of curing it.
Conclusions
Chlorhexidine causes contact
more commonly than immediate
allergy. It is known that IgE-medi-
ated allergy to chlorhexidine may
even cause severe general reactions
when chlorhexidine-containing
antiseptic preparations are used,
for example in association with
surgical measures (1). However,
patients with a weak skin test re-
action often only react to topical
use with mild redness in the skin
(2). As an antimicrobial substance,
chlorhexidine may be contained in
cosmetics and medical ointments,
surgical soaps, tooth pastes,
mouth washes, and hand and
wound cleaning agents. The fact
that chlorhexidine could be found
in oral preparations which are ab-
sorbed in the body, came as a sur-
prise even to the doctor. Accord-
ing to a report of the National
Agency for Medicines, besides the
throat lozenges used by our pa-
tient, chlorhexidine is not found
in other corresponding over-the-
counter products available on the
market in Finland. In addition to
the topical ointments commonly
used and also available as OTC
products,  small amounts of
chlorhexidine are found in a few
varieties of nose sprays, vaginal
ointments, oral gels and solutions
and stomach acid neutralising
products.
On examining patients who
have developed sudden urticaria,
angioedema or a complicated re-
action of the anaphylactic type, a
careful assessment of the products
previously used by the patient, in-
cluding their composition, is rec-
ommended. An allergen which is
well-known and judged as quite
common may sometimes unex-
pectedly be found in a product.
Literature see page 23
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Own observation of an
adverse reaction
Heli Halava
Specialist Physician
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